BNTX — BioNTech SE
Is BNTX overbought or oversold? Here is the current MarketMoodz read.
BioNTech SE (BNTX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $84.86. The rating moved from Neutral to Oversold on November 5, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$84.86
- Last changeMoved from Neutral to Oversold on November 5, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
BioNTech SE combines a leading mRNA technology base with a multi-program pipeline that supports medium-term growth potential, while near-term financials are exposed to COVID-19 vaccine revenue normalization. Existing commercial experience and partnerships provide operational strength and optionality, but clinical, competitive and regulatory execution risk remain material. Expect price consolidation in the near term with episodic moves tied to trial readouts, partnership announcements, or changes in vaccine demand dynamics.
Key factors
- Leading mRNA platform and strong scientific capabilities underpin long-term pipeline potential
- Diversified pipeline across oncology, infectious diseases and personalized cancer vaccines offers multiple catalyst pathways
- Prior commercial experience and partnerships (e.g., COVID-19 vaccine commercialization) provide scale, manufacturing know-how and cash generation, but revenue normalization is underway
- Strategic collaborations and licensing arrangements help de-risk late-stage development and market access
- Valuation currently reflects material execution and clinical risk, limiting near-term upside absent positive readouts or repricing events
- Macro market tone is consolidative with defensive flows favoring large-cap pharma; Biotech-specific flows remain selective
Risks
- Revenue decline as COVID-19 vaccine demand normalizes and potential seasonality of booster uptake
- Clinical trial setbacks or delayed readouts in key oncology and personalized vaccine programs
- Intensifying competition from other mRNA developers, large vaccine franchises and novel modalities
- Regulatory, pricing and reimbursement pressures that could cap commercial potential
- Manufacturing, supply-chain or scale-up issues that affect deliveries or margins
- Capital markets volatility that could limit refinancing or M&A outcomes and increase funding costs
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for BNTX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.